Volume 67, Issue 6, Pages (June 2005)

Slides:

Advertisements

Similar presentations

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Advertisements

Improved prognosis of diabetic nephropathy in type 1 diabetes

Volume 55, Issue 2, Pages (February 1999)

Plasma sodium and hypertension

Frederik Persson, Peter Rossing Kidney International Supplements

Blaithin A. McMahon, Patrick Thomas Murray Kidney International

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Volume 85, Issue 2, Pages (January 2014)

Prehypertension and chronic kidney disease: the ox or the plow?

Volume 80, Issue 10, Pages (November 2011)

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

John P. Middleton, Patrick H. Pun Kidney International

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Volume 77, Issue 8, Pages (April 2010)

Volume 55, Issue 2, Pages (February 1999)

Volume 57, Pages S32-S37 (April 2000)

Volume 77, Issue 1, Pages 5-6 (January 2010)

Progression of diabetic nephropathy

Volume 54, Issue 4, Pages (October 1998)

Volume 74, Issue 3, Pages (August 2008)

Targets to retard the progression of diabetic nephropathy

Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion Lynda A. Frassetto, Eileen Nash,

Volume 73, Issue 4, Pages (February 2008)

Renal risk scores: Progress and prospects

Volume 55, Issue 3, Pages (March 1999)

The role of protein kinase C activation in diabetic nephropathy

U-shaped effect of eGFR and mortality

Volume 67, Pages S48-S51 (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Volume 57, Issue 1, Pages (January 2000)

Volume 85, Issue 3, Pages (March 2014)

Capturing the in vivo molecular signature of the podocyte

Volume 53, Issue 4, Pages (April 1998)

Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1 Peter Hovind, MD, Lise Tarnow, MD, Peter Rossing,

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 63, Pages S38-S42 (February 2003)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 56, Issue 2, Pages (August 1999)

Volume 67, Issue 4, Pages (April 2005)

Volume 66, Issue 3, Pages (September 2004)

Nephrology Crossword: Glomerulonephritis

The initiation and progression of sickle cell nephropathy

Volume 74, Issue 5, Pages (September 2008)

Improved prognosis of diabetic nephropathy in type 1 diabetes

Volume 85, Issue 5, Pages (May 2014)

Volume 60, Issue 1, Pages (July 2001)

Volume 80, Issue 3, Pages (August 2011)

Douglas G Matsell, Colin T White Kidney International

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Volume 60, Issue 1, Pages (July 2001)

Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis Sunil Gupta, Michael R. Clarkson, Joseph Duggan,

Volume 80, Issue 10, Pages (November 2011)

Volume 61, Issue 3, Pages (March 2002)

Volume 72, Issue 11, Pages (December 2007)

Volume 70, Issue 3, Pages (August 2006)

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Volume 56, Issue 4, Pages (October 1999)

Volume 62, Issue 5, (November 2002)

Volume 68, Issue 3, Pages (September 2005)

Volume 58, Issue 2, Pages (August 2000)

Volume 55, Issue 3, Pages (March 1999)

Volume 68, Issue 3, Pages (September 2005)

Volume 53, Issue 5, Pages (May 1998)

Volume 58, Issue 5, Pages (November 2000)

Volume 57, Issue 2, Pages (October 2000)

Volume 79, Issue 10, Pages (May 2011)

Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis Eero O. Honkanen, Anna-Maija Teppo, Carola.

Presentation transcript:

Volume 67, Issue 6, Pages 2325-2329 (June 2005) Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy Steen Andersen, Frans A. van Nieuwenhoven, Lise Tarnow, Peter Rossing, Kasper Rossing, Lotte Wieten, Roel Goldschmeding, Hans- Henrik Parving Kidney International Volume 67, Issue 6, Pages 2325-2329 (June 2005) DOI: 10.1111/j.1523-1755.2005.00337.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Urinary connective tissue growth factor (CTGF) excretion in hypertensive type 1 diabetic patients with diabetic nephropathy during Losartan treatment. All P < 0.05 vs. baseline. Kidney International 2005 67, 2325-2329DOI: (10.1111/j.1523-1755.2005.00337.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Scatterplots of (A) changes in albuminuria vs. changes in urinary connective tissue growth factor (CTGF)(r = 0.54,P < 0.01)and (B) rate of decline in glomerular filtration rate (GFR) vs. changes in urinary CTGF(r = 0.23, P = 0.05). Kidney International 2005 67, 2325-2329DOI: (10.1111/j.1523-1755.2005.00337.x) Copyright © 2005 International Society of Nephrology Terms and Conditions